Neuropeptide
Nociceptin
Nociceptin, also known as orphanin FQ, was identified in searches for ligands of structurally opioid-related receptors. Its history shows why receptor or peptide similarity is insufficient to assign the pharmacology of an entire family.
This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
The readout depends on the nervous-system model
Describe the model before the result. A cellular signal, behavioral observation and clinical outcome are not interchangeable evidence labels.
- Is the study examining an isolated receptor, cells, a brain region or an entire organism?
- Does the work distinguish measured concentration, exposure and observed response?
- Does the behavior or marker measured have explicit controls and limits?
Mechanism described in the literature
Identification studies observed adenylyl cyclase inhibition in vitro in cells expressing the investigated receptor, called ORL1 or LC132 in those publications. Identification combined ligand recognition and functional response.
Other names in the literature
- Nociceptin
- Orphanin FQ
- N/OFQ
An orphan receptor guided the search
One investigation isolated the peptide by tracking activity in CHO cells expressing ORL1. Another purified it from porcine brain as an LC132 ligand. These historical names reflect convergent discovery programs. Identifying both material and receptor brings this literature together without confusing it with other opioid peptides.
Structural relationship and pharmacology are not equivalent
In vitro, the orphanin FQ study found that tested opioid ligands did not alter the measured inhibitory activity and that the peptide did not activate the opioid receptors evaluated. This is a specific pharmacological comparison; sequence similarity cannot replace selectivity assays.
Behavioral assays are not interchangeable either
Animal publications described nociceptive and locomotor responses. The orphanin FQ study found different results in hot-plate and tail-withdrawal tests, preventing the peptide's name from becoming a universal conclusion about pain. The measured variable, experimental system and manipulation must accompany each finding; cellular enzyme activity alone does not predict all behavioral readouts.
Questions and answers
Are nociceptin and orphanin FQ names for two ingredients?
They are names for the same entity discovered through independent research programs.
Does its opioid relationship determine an analgesic response?
No. The cited assays document distinct pharmacology and results dependent on the animal test.
Sources
- Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. — Nature, 1995
- Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.
- Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. — Science, 1995
- Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.